Reduced benefits: Using doses that are too low may limit benefit, while stopping or adjusting treatment without follow-up can interfere with long-term metabolic or health goals
Clinical trial data provides objective evidence about efficacy (24.2% weight loss at 48 weeks), safety (88.8% completion rate), side effects (peak at weeks 6-8, resolve by week 12 for most), and discontinuation outcomes (70-80% regain over 12-18 months, not immediately)
For diabetes management, semaglutide can be used as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and insulin
Most GLP-1s are started at a low dose and then slowly increased to minimize potential side effects
Please share it with others
Hims & Hers Hims & Hers uses a similar membership-plus-medication model and the same $149 ongoing membership